BNP PARIBAS ASSET MANAGEMENT Holding S.A.
Position in DNLI — Denali Therapeutics Inc.
CIK 1520354
Paris, I0
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$34,863,820
+$29,170,964 QoQ
Shares Held
1,355,514
+357.2% QoQ
Ownership
0.848%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#29
of 293 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BNP PARIBAS ASSET MANAGEMENT Holding S.A. holds $2,249,207,592 across 136 Biotechnology names. DNLI ranks #20 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
897,893 | $446,010,389 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
331,560 | $206,740,921 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
799,297 | $192,606,596 | |
| 4 | ARGX |
Argenx SE
|
121,786 | $112,989,396 | |
| 5 | INCY |
Incyte Corp
|
937,763 | $106,304,813 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
1,290,731 | $77,908,522 | |
| 7 | VCEL |
Vericel Corp
|
1,639,988 | $72,963,065 | |
| 8 | CYTK |
Cytokinetics Inc
|
827,810 | $70,521,132 |
All Filings in DNLI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,863,820 | 1,355,514 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $5,692,856 | 296,503 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $4,933,055 | 298,792 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $18,454 | 1,271 | Shares | Defined | 2025-11-07 | |
| 2025-06-30 | $15,934 | 1,139 | Shares | Defined | 2025-08-06 | |
| No filing history on record for this holder in this stock. | ||||||